Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
Global Biopharma Solutions Leader Selects Kneat to Drive Digital Validation Excellence
LIMERICK, Ireland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI)…
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON”…
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025 16:15 ET | Source: Zenas BioPharma WALTHAM, Mass., Dec.…
Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
Registrations OPEN India's first of-its-kind, 6th Annual Summit on Biopharmaceutical Product Development in conjunction…
COSCIENS Biopharma Inc. Announces Leadership Change
TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX:…
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
November 11, 2025 07:05 ET | Source: Zenas BioPharma WALTHAM, Mass., Nov.…
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Investor webcast to be held on Monday November 3, 2025 at 8:00…
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc"…
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
August 26, 2025 08:00 ET | Source: Cogent Biosciences, Inc. WALTHAM, Mass.…
